### Highlights of This Issue 2675

#### SMALL MOLECULE THERAPEUTICS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2677</td>
<td>Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer</td>
<td>Rebecca A. Previs, Guillermo N. Armaiz-Pena, Yvonne G. Lin, Ashley N. Davis, Sunila Pradeep, Heather J. Dalton, Robert L. Coleman, and Anil K. Sood</td>
</tr>
<tr>
<td>2677</td>
<td>Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases</td>
<td>Kazuharu Kai, Kimie Kondo, Xiaoping Wang, Xuemei Xie, Monica E. Reyes, Angie M. Torres-Adorno, Debu Tripathy, Subrata Sen, and Naoto T. Ueno</td>
</tr>
<tr>
<td>2700</td>
<td>Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors</td>
<td>Steven R. Whittaker, Glenn S. Cowley, Steve Wagner, Flori Luo, David E. Root, and Levi A. Garraway</td>
</tr>
<tr>
<td>2712</td>
<td>Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma</td>
<td>Matthias Ilmer, Agnès Garnier, Jody Vykoukal, Eckhard Alt, Dietrich von Schweinitz, Roland Kappler, and Michael Berger</td>
</tr>
<tr>
<td>2722</td>
<td>Silibinin Preferentially Radiosensitizes Prostate Cancer by Inhibiting DNA Repair Signaling</td>
<td>Dhanya K. Nambiar, Paulraj Rajamani, Gagan Deep, Anil K. Jain, Rajesh Agarwal, and Rana P. Singh</td>
</tr>
</tbody>
</table>

#### LARGE MOLECULE THERAPEUTICS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2744</td>
<td>The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo</td>
<td>Heather Venant, Mehrdad Rahmaniyan, E. Ellen Jones, Ping Lu, Michael B. Lilly, Elizabeth Garrett-Mayer, Richard R. Drake, Jacqueline M. Kavetska, Charles D. Smith, and Christina Voelkel-Johnson</td>
</tr>
<tr>
<td>2782</td>
<td>MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model</td>
<td>Chandra Bartholomeusz, Xuemei Xie, Mary Kathryn Pitner, Kimie Kondo, Ali Dadbin, Jangsoon Lee, Hitomi Saso, Paul D. Smith, Kevin N. Dalby, and Naoto T. Ueno</td>
</tr>
</tbody>
</table>

December 2015 • Volume 14 • Number 12
Systemic Administration and Targeted Radiosensitization via Chemically Synthetic Aptamer–siRNA Chimeras in Human Tumor Xenografts
Xiaohua Ni, Yonggang Zhang, Kenji Zennami, Mark Castanares, Amarnath Mukherjee, Raju R. Raval, Haoming Zhou, Theodore L. DeWeese, and Shawn E. Lupold

A TORC2–Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers
Dhara N. Amin, Deepika Ahuja, Paul Yaswen, and Mark M. Moasser

PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway
Florian Engert, Cornelius Schneider, Lilly Magdalena Weiß, Marie Probst, and Simone Fulda

ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor
Yoshito Nakashima, Hideaki Mizuno, Hitoshi Sase, Toshihiko Fujii, Kyōoaki Sakata, UKinorii Akiyama, Yuku Aoki, Masahiro Aoki, and Nobuya Ishii

Pigment Epithelium–Derived Factor Alleviates Tamoxifen-Induced Endometrial Hyperplasia

Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model

Genome-Wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma
Wei Jiang, Na Li, Xiaozhong Chen, Ying Sun, Bin Li, Xian-Yue Ren, Wei-Feng Qin, Ning Jang, Ya-Fei Xu, Ying-Qin Li, Jian Ren, William CS Cho, Jing-Ping Yun, Jing Zeng, Li-Zhi Liu, Li Li, Ying Guo, Hai-Qiang Mai, Mu-Sheng Zeng, Tie-Rang Kang, Wei-Hua Jia, Jian-Qiong Shao, and Jun Ma

Severely Impaired and Dysregulated Cytochrome P450 Expression and Activities in Hepatocellular Carcinoma: Implications for Personalized Treatment in Patients
Tong Meng Yan, Linlin Lu, Cong Xie, Jianmei Chen, Xiaojun Peng, Lijun Zhu, Ying Wang, Qiang Li, Jian Shi, Fuyuan Zhou, Ming Hu, and Zhongqiu Liu

Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing

Clinical and Translational Assessment of VEGFR1 as a Mediator of the Premetastatic Niche in High-Risk Localized Prostate Cancer
Sumanta Kumar Pal, Winston Vuong, Wang Zhang, Jiehui Deng, Xuelun Liu, Courtney Carmichael, Nora Ruel, Manasvi Pinnamaneni, Przemyslaw Twardowski, Clayton Lau, Hua Yu, Robert A. Figlin, Neeraj Agarwal, and Jeremy O. Jones

Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model
Vlad C. Sandulache, Yunyun Chen, Heath D. Skinner, Tongtong Lu, Lei Peng, Laurence E. Court, Jeffrey N. Myers, Raymond E. Meyn, Clifton D. Fuller, James A. Bankson, and Stephen T. Lai

Acknowledgment to Reviewers

AC icon indicates Author Choice
For more information please visit www.aacrjournals.org
ABOUT THE COVER

The cover image shows the structural model of LMB-T20, a highly potent recombinant immunotoxin consisting of an antimesothelin Fv fused to a portion of *Pseudomonas* exotoxin A. The toxin has a deletion of domain II and six point mutations in domain III that delete or greatly suppress the eight T-cell epitopes. For details, see the article by Mazor and colleagues on page 2789.
Molecular Cancer Therapeutics

14 (12)

Mol Cancer Ther 2015;14:2675-2912.

Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/14/12

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.